Tag Archive for: PSMA

CEACAM5 Radiotheranostics: A Targeted Strategy for PSMA-Negative, Neuroendocrine Prostate Cancer

For prostate cancer patients with low expression of PSMA or with neuroendocrine prostate cancer or NEPC (a population growing in size precisely because better treatments are forcing tumors to adapt), a new preclinical study offers a credible precision-targeted strategy: a radiotheranostic pair built on the CEACAM5 surface antigen that produced complete tumor responses in every […]

QLS2401: A Trispecific PSMA/STEAP1/CD3 T‑Cell Engager for mCRPC

QLS2401 is a trispecific T‑cell engager designed for metastatic castration‑resistant prostate cancer (mCRPC). It binds three targets at once: PSMA and STEAP1 on tumor cells, plus CD3 on T cells. This design allows it to physically connect a patient’s T cells to prostate‑cancer cells, triggering T‑cell activation and killing of the tumor. Both PSMA and […]

UPDATE: Phase 1 GenSci143 Trial Set To Start By The End of December

We have already talked about it here, GenSci143, is a novel bispecific antibody-drug conjugate targeting B7-H3 and PSMA, and a phase 1 trial is set to begin first-in-human clinical trials soon (est. date December 20) in participants with advanced solid tumors, including metastatic castration-resistant prostate cancer. Recent regulatory approvals were granted by the U.S. FDA […]

APVO442: A Promising Preclinical Candidate in the Fight Against Prostate Cancer

A Seattle-based biotech, is stepping up with APVO442, a promising preclinical bispecific antibody aimed at transforming prostate cancer treatment by unleashing the body’s immune system against tumors with greater precision and fewer side effects. Built on proprietary ADAPTIR-FLEX platform, APVO442 is designed to target prostate-specific membrane antigen (PSMA), a protein highly expressed on prostate cancer […]

Phase 1 Recruiting: ABBV-969, A Novel Bispecific Antibody Drug Conjugate for Advanced Prostate Cancer

CTT2274: A Potential Game-Changer for Metastatic Prostate Cancer Treatment…start hating the word “potential”